BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37796708)

  • 21. Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'.
    Bredemeier M
    Ann Rheum Dis; 2022 Dec; 81(12):e250. PubMed ID: 33023963
    [No Abstract]   [Full Text] [Related]  

  • 22. Histopathology of pulmonary fibrotic disorders.
    Lai CK; Wallace WD; Fishbein MC
    Semin Respir Crit Care Med; 2006 Dec; 27(6):613-22. PubMed ID: 17195138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
    Lamb YN
    Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.
    González-Sánchez E; Muñoz-Callejas A; Gómez-Román J; San Antonio E; Marengo A; Tsapis N; Bohne-Japiassu K; González-Tajuelo R; Pereda S; García-Pérez J; Cavagna L; González-Gay MÁ; Vicente-Rabaneda EF; Meloni F; Fattal E; Castañeda S; Urzainqui A
    Br J Pharmacol; 2022 Sep; 179(18):4534-4548. PubMed ID: 35726496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings.
    Kim EA; Lee KS; Johkoh T; Kim TS; Suh GY; Kwon OJ; Han J
    Radiographics; 2002 Oct; 22 Spec No():S151-65. PubMed ID: 12376608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
    Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
    Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of pirfenidone on fibroblast to myofibroblast transition in rheumatoid arthritis-associated interstitial lung disease via the downregulation of activating transcription factor 3 (ATF3).
    Wu C; Lin H; Zhang X
    Int Immunopharmacol; 2019 Sep; 74():105700. PubMed ID: 31228816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
    Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
    Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
    Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence.
    Richeldi L; Varone F; Bergna M; de Andrade J; Falk J; Hallowell R; Jouneau S; Kondoh Y; Morrow L; Randerath W; Strek M; Tabaj G
    Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary fibrosis: from pathogenesis to clinical decision-making.
    Koudstaal T; Funke-Chambour M; Kreuter M; Molyneaux PL; Wijsenbeek MS
    Trends Mol Med; 2023 Dec; 29(12):1076-1087. PubMed ID: 37716906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study.
    Theodore AC; Tseng CH; Li N; Elashoff RM; Tashkin DP
    Chest; 2012 Sep; 142(3):614-621. PubMed ID: 22156609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrating Genomics Into Management of Fibrotic Interstitial Lung Disease.
    Adegunsoye A; Vij R; Noth I
    Chest; 2019 May; 155(5):1026-1040. PubMed ID: 30660786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis.
    Su R; Bennett M; Jacobs S; Hunter T; Bailey C; Krishnan E; Rosen G; Chung L
    J Rheumatol; 2011 Apr; 38(4):693-701. PubMed ID: 21285162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 37. [New developments in systemic sclerosis-associated interstitial lung disease].
    Humair G; Daccord C; Beigelman-Aubry C; Lazor R
    Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of COVID-19 and other viral infections with interstitial lung diseases, pulmonary fibrosis, and pulmonary hypertension: A narrative review.
    Atabati E; Dehghani-Samani A; Mortazavimoghaddam SG
    Can J Respir Ther; 2020; 56():1-9. PubMed ID: 33274259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
    Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
    Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
    [No Abstract]   [Full Text] [Related]  

  • 40. Interstitial lung disease in scleroderma.
    Schoenfeld SR; Castelino FV
    Rheum Dis Clin North Am; 2015 May; 41(2):237-48. PubMed ID: 25836640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.